AstralBio
Private Company
Funding information not available
Overview
AstralBio is an early-stage biotech based in San Diego, CA, with a secondary office in Boston, MA, focusing on AI-driven antibody discovery for cardiometabolic and immune-mediated diseases. Founded by experienced antibody developers from ValenzaBio and AlmataBio, the company is building on a proven computational platform to identify and advance novel biologics. As a private, pre-clinical entity, it is positioned to rapidly generate pipeline candidates by integrating machine learning with traditional biologics expertise. The company's success will hinge on validating its platform and translating its computational hits into effective clinical-stage therapeutics.
Technology Platform
A machine learning-enabled platform for the discovery and optimization of antibody therapeutics, designed to accelerate the identification of novel drug candidates.
Opportunities
Risk Factors
Competitive Landscape
AstralBio competes with a growing number of AI-native biotechs (e.g., Recursion, Exscientia, Insitro) as well as established biopharma companies investing heavily in computational discovery. In antibody therapeutics, it faces competition from both large biologics firms and numerous biotech startups targeting similar disease areas with varied modalities.